Table 3 Comparison of different DBPCFC evaluation criteria
EuroPrevall [28; from 2015] | PRACTALL [8, from 2012] | This trial (2008) | |
|---|---|---|---|
Scoring | Objective signs absent/present Subjective symptoms: persistent > 45 min | Objective signs and subjective symptoms 0 = absent, 1 = mild, 2 = moderate, 3 = severe | Objective signs: present/absent Subjective symptoms: VAS (0–10 cm) |
Skin/mucosa | Blisters of oral mucosa (O) Skin flushing (O) Urticaria (O) Angioedema (O) Conjunctivitis (O) Itching of palms, soles head (S) | Pruritus (S) Urticaria/angioedema (O) Rash (O) | O1 Intraoral swelling/blistering O2 Flush O3 Urticaria O4 Angioedema O5 Conjunctivitis S1 Intraoral tingling/itching S2 Perceived lip swelling S3 Itching skin/eye/nose |
Upper respiratory tract | Rhinitis (O) | Sneezing/itching (S/O) | O6 Rhinitis S3 Itching nose |
Lower respiratory tract | Drop of FEV1 > 12% or drop of PEF > 20% (O) Laryngeal edema (O) | Wheezing (O) Laryngeal (O) | O7 Peak flow reduction > 20% S5 Dyspnea |
Gastrointestinal tract | Diarrhea (O) Emesis (S) Severe gastric/abdominal pain (S) | Itchy mouth/throat, nausea, pain (S) emesis, diarrhea (O) | O10 Diarrhea, vomiting S4 Dysphagia S6 Nausea S7 Abdominal pain |
Cardiovascular/neurological system | Drop of BP > 20 mmHg (O) | Heart rate increase or drop in blood pressure, dizziness, unconsciousness (O/S) | O8 Drop of BP > 20 mmHg O9 Increase of heart rate > 20% S8 Dizziness |